Article Cited by others

INVITED REVIEW

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications

Singh B Harpreet, Gulley James L

Year : 2014| Volume: 16| Issue : 3 | Page no: 364-371

   This article has been cited by
 
1 Modeling the effect of immunotherapies on human castration-resistant prostate cancer
Roberta Coletti,Andrea Pugliese,Luca Marchetti
Journal of Theoretical Biology. 2020; : 110500
[Pubmed]  [Google Scholar] [DOI]
2 Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
Ravi A Madan,Emmanuel S Antonarakis,Charles G Drake,Lawrence Fong,Evan Y Yu,Douglas G McNeel,Daniel W Lin,Nancy N Chang,Nadeem A Sheikh,James L Gulley
JNCI: Journal of the National Cancer Institute. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
James L. Gulley,Ravi A. Madan,Russell Pachynski,Peter Mulders,Nadeem A. Sheikh,James Trager,Charles G. Drake
JNCI: Journal of the National Cancer Institute. 2017; 109(4)
[Pubmed]  [Google Scholar] [DOI]
4 Ipilimumab for the treatment of metastatic prostate cancer
Concetta Alaia,Mariarosaria Boccellino,Silvia Zappavigna,Evzen Amler,Lucio Quagliuolo,Sabrina Rossetti,Gaetano Facchini,Michele Caraglia
Expert Opinion on Biological Therapy. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
5 The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis
Liang Zhou,Xi-Ling Wang,Qing-Long Deng,Yan-Qiu Du,Nai-Qing Zhao
Scientific Reports. 2016; 6: 32020
[Pubmed]  [Google Scholar] [DOI]
6 The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G. McNeel,Neil H. Bander,Tomasz M. Beer,Charles G. Drake,Lawrence Fong,Stacey Harrelson,Philip W. Kantoff,Ravi A. Madan,William K. Oh,David J. Peace,Daniel P. Petrylak,Hank Porterfield,Oliver Sartor,Neal D. Shore,Susan F. Slovin,Mark N. Stein,Johannes Vieweg,James L. Gulley
Journal for ImmunoTherapy of Cancer. 2016; 4(1)
[Pubmed]  [Google Scholar] [DOI]
7 Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab
Serena S. Kwek,Jera Lewis,Li Zhang,Vivian Weinberg,Samantha K. Greaney,Andrea L. Harzstark,Amy M. Lin,Charles J. Ryan,Eric J. Small,Lawrence Fong
Cancer Immunology Research. 2015; 3(9): 1008
[Pubmed]  [Google Scholar] [DOI]
8 Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting
Andrea K. Miyahira,Haydn T. Kissick,Jennifer L. Bishop,David Y. Takeda,Christopher E. Barbieri,Jonathan W. Simons,Kenneth J. Pienta,Howard R. Soule
The Prostate. 2015; 75(4): 337
[Pubmed]  [Google Scholar] [DOI]
9 Sequencing current therapies in the treatment of metastatic prostate cancer
Loana B Valenca,Christopher Sweeney,Mark M Pomerantz
Cancer Treatment Reviews. 2015;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article